2,244 research outputs found
Promoting adherence to antiretroviral therapy: the experience from a primary care setting in Khayelitsha, South Africa.
OBJECTIVE: To describe the approach used to promote adherence to antiretroviral therapy (ART) and to present the outcomes in the first primary care public sector ART project in South Africa. DESIGN: The study is a prospective open cohort, including all adult patients naive to previous ART who received antiretroviral treatment in Khayelitsha, from May 2001 to the end of 2002. Patients were followed until their most recent visit before 31 July 2003. METHODS: Plasma viral load was determined at 3, 6, 12, 18 and 24 months after ART was initiated, and CD4 cell counts 6-monthly. Kaplan-Meier estimates were determined for the cumulative proportions of patients surviving, and patients with viral load suppression and viral rebound. RESULTS: A total of 287 patients were initiated on triple therapy. The probability of survival was 86.3% at 24 months. The median CD4 cell count gain was 288 cells/microliters at 24 months. Viral load was less than 400 copies/ml in 89.2, 84.2 and 69.7% of patients at 6, 12 and 24 months, respectively. The cumulative probability of viral rebound (two consecutive HIV-RNA measurements above 400 copies/ml) after achieving an HIV-RNA measurement below 400 copies/ml was 13.2% at 18 months. CONCLUSION: The study shows that, with a standard approach to patient preparation and strategies to enhance adherence, a cohort of patients on ART can be retained in a resource-limited setting in a developing country. A high proportion of patients achieved suppression of viral replication. The subsequent probability of viral rebound was low
Review: Khayelitsha 2001 - 2011: 10 years of primary care HIV and TB programmes
Tuberculosis (TB) and HIV care in Khayelitsha, and in South Africa as a whole, has overcome numerous obstacles in the past three decades. This article highlights what has been achieved in Khayelitsha, describes the key clinical programme and policy changes that have supported universal coverage for HIV and TB care over the last 10 years, and outlines the challenges for the next decade
ΠΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΊΠ°ΠΏΠ΅ΡΠΈΡΠ°Π±ΠΈΠ½Π° ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ 5-ΡΡΠΎΡΡΡΠ°ΡΠΈΠ»ΠΎΠΌ ΠΏΡΠΈ ΡΠ°ΠΊΠ΅ ΡΠΎΠ»ΡΡΠΎΠΉ ΠΊΠΈΡΠΊΠΈ ΠΈ ΠΆΠ΅Π»ΡΠ΄ΠΊΠ°: ΠΎΠ±Π½ΠΎΠ²Π»Π΅Π½Π½ΡΠΉ ΠΌΠ΅ΡΠ°Π°Π½Π°Π»ΠΈΠ· Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΠΈ Π² ΡΠ΅ΡΡΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡΡ
ΠΡΠ°Π»ΡΠ½ΡΠΉ ΡΡΠΎΡΠΏΠΈΡΠΈΠΌΠΈΠ΄ΠΈΠ½ β ΠΊΠ°ΠΏΠ΅ΡΠΈΡΠ°Π±ΠΈΠ½ β ΡΠΈΡΠΎΠΊΠΎ ΠΈΠ·ΡΡΠ΅Π½ Π² ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΡΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡΡ
Ρ Π²Π²ΠΎΠ΄ΠΈΠΌΡΠΌ Π²Π½ΡΡΡΠΈΠ²Π΅Π½Π½ΠΎ 5-ΡΡΠΎΡΡΡΠ°ΡΠΈΠ»ΠΎΠΌ ΠΊΠ°ΠΊ ΠΌΠΎΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΡΡΠ΅Π΄ΡΡΠ²ΠΎ ΠΈΠ»ΠΈ Π² ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΌ ΠΏΡΠΈΠΌΠ΅- Π½Π΅Π½ΠΈΠΈ ΠΏΡΠΈ ΠΌΠ΅ΡΠ°ΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΌ ΠΊΠΎΠ»ΠΎΡΠ΅ΠΊΡΠ°Π»ΡΠ½ΠΎΠΌ ΡΠ°ΠΊΠ΅ (ΠΠΠ Π ) ΠΈ ΠΌΠ΅ΡΠ°ΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΌ ΡΠ°ΠΊΠ΅ ΠΆΠ΅Π»ΡΠ΄ΠΊΠ° (ΠΠ Π). ΠΠΎ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°ΡΠΈΠΈ ΠΠ²ΡΠΎΠΏΠ΅ΠΉΡΠΊΠΈΡ
ΠΎΡΠ³Π°Π½ΠΎΠ² Π·Π΄ΡΠ°Π²ΠΎΠΎΡ
ΡΠ°Π½Π΅Π½ΠΈΡ Π²ΡΠΏΠΎΠ»Π½Π΅Π½ ΠΌΠ΅ΡΠ°Π°Π½Π°Π»ΠΈΠ· ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΊΠ°ΠΏΠ΅ΡΠΈΡΠ°Π±ΠΈΠ½Π° ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ 5-ΡΡΠΎΡΡΡΠ°ΡΠΈΠ»ΠΎΠΌ ΠΏΡΠΈ ΠΠΠ Π ΠΈ ΠΠ Π
Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial.
BACKGROUND: Preoperative treatment of resectable liver metastases from colorectal cancer (CRC) is a matter of debate. The aim of this study was to assess the feasibility and activity of bevacizumab plus FOLFIRI in this setting. METHODS: Patients aged 18-75 years, PS 0-1, with resectable liver-confined metastases from CRC were eligible. They received bevacizumab 5 mg kg(-1) followed by irinotecan 180 mg m(-)(2), leucovorin 200 mg m(-)(2), 5-fluorouracil 400 mg m(-)(2) bolus and 5-fluorouracil 2400 mg m(-)(2) 46-h infusion, biweekly, for 7 cycles. Bevacizumab was stopped at cycle 6. A single-stage, single-arm phase 2 study design was applied with 1-year progression-free rate as the primary end point, and 39 patients required. RESULTS: From October 2007 to December 2009, 39 patients were enrolled in a single institution. Objective response rate was 66.7% (95% exact CI: 49.8-80.9). Of these, 37 patients (94.9%) underwent surgery, with a R0 rate of 84.6%. Five patients had a pathological complete remission (14%). Out of 37 patients, 16 (43.2%) had at least one surgical complication (most frequently biloma). At 1 year of follow-up, 24 patients were alive and free from disease progression (61.6%, 95% CI: 44.6-76.6). Median PFS and OS were 14 (95% CI: 11-24) and 38 (95% CI: 28-NA) months, respectively. CONCLUSION: Preoperative treatment of patients with resectable liver metastases from CRC with bevacizumab plus FOLFIRI is feasible, but further studies are needed to define its clinical relevance
Aflibercept in the Treatment of Metastatic Colorectal Cancer
Colorectal cancer is the third most common cancer in the US. In recent decades, an improved understanding of the role of the angiogenesis pathway in colorectal cancer has led to advancements in treatment. Bevacizumab has been shown to improve the progression-free survival and overall survival when combined with cytotoxic chemotherapy in patients with metastatic colorectal cancer, and at present is the only antiangiogenesis agent approved for the treatment of this cancer. Aflibercept is a novel angiogenesis-targeting agent, and has demonstrated efficacy in treating metastatic colorectal cancer in a recent randomized Phase III trial. Here we review the role of angiogenesis in the tumorigenesis of colorectal cancer, strategies for targeting angiogenesis, and the clinical development of aflibercept
Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study
Ibrutinib; Metastatic pancreatic adenocarcinoma; Phase IIIIbrutinib; Adenocarcinoma de pΓ‘ncreas metastΓ‘sico; Fase IIIIbrutinib; Adenocarcinoma de pΓ ncrees metastΓ tic; Fase IIIFirst-line treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) includes nab-paclitaxel/gemcitabine. Ibrutinib, a Bruton's tyrosine kinase inhibitor, exhibits antitumor activity through tumor microenvironment modulation. The safety and efficacy of first-line ibrutinib plus nab-paclitaxel/gemcitabine treatment in patients with PDAC were evaluated.
Patients and methods
RESOLVE (NCT02436668) was a phase III, randomized, double-blind, placebo-controlled study. Patients (histologically-confirmed PDAC; stage IV diagnosis β₯6 weeks of randomization; Karnofsky performance score β₯70) were randomized to once-daily oral ibrutinib (560 mg) or placebo plus nab-paclitaxel (125 mg/m2) and gemcitabine (1000 mg/m2). Primary endpoints were overall survival (OS) and investigator-assessed progression-free survival (PFS); overall response rate and safety were assessed.
Results
In total, 424 patients were randomized (ibrutinib arm, n = 211; placebo arm, n = 213). Baseline characteristics were balanced across arms. After a median follow-up of 25 months, there was no significant difference in OS between ibrutinib plus nab-paclitaxel/gemcitabine versus placebo plus nab-paclitaxel/gemcitabine (median of 9.7 versus 10.8 months; P = 0.3225). PFS was shorter for ibrutinib plus nab-paclitaxel/gemcitabine compared with placebo plus nab-paclitaxel/gemcitabine (median 5.3 versus 6.0 months; P < 0.0001). Overall response rates were 29% and 42%, respectively (P = 0.0058). Patients in the ibrutinib arm had less time on treatment and received lower cumulative doses for all agents compared with the placebo arm. The most common grade β₯3 adverse events for ibrutinib versus placebo arms included neutropenia (24% versus 35%), peripheral sensory neuropathy (17% versus 8%), and anemia (16% versus 17%). Primary reasons for any treatment discontinuation were disease progression and adverse events.
Conclusions
Ibrutinib plus nab-paclitaxel/gemcitabine did not improve OS or PFS for patients with PDAC. Safety was consistent with known profiles for these agents.This work was supported by Pharmacyclics LLC, an AbbVie Company (no grant number)
Ethylene C2H3D isotopologue: high resolution study of v6, v4, v8, v7 and v10 fundamentals
High Resolution Fourier transform infrared spectra of the C2H3D molecule were recorded with Doppler limited resolution in the region of 600 - 1250 cm-1 at room temperature. The measurements were carried out under several different absorption conditions using the Bruker 120 HR spectrometer in Braunschweig Technical University. Five fundamentals v6, v4, v8, v7, and v10 were observed and found to be perturbed by different resonance interactions. About 6000 lines were assigned in the recorded spectrum. They were used then in the weighted fit procedure with the effective Hamiltonian taking into account five strongly interacting states
- β¦